ATAI Life Sciences Files 8-K, Confirms Nasdaq Listing

TL;DR

**ATAI Life Sciences filed a routine 8-K, confirming its Nasdaq listing and compliance.**

AI Summary

ATAI Life Sciences N.V. filed an 8-K on January 9, 2024, reporting an event that occurred on January 7, 2024. This filing is a routine update to their registration statement, specifically noting their common shares, with a €0.10 par value per share, are traded on The Nasdaq Stock Market LLC (Nasdaq Global Market) under the symbol ATAI. This matters to investors as it confirms the company's continued compliance with SEC regulations and its listing on a major exchange, which is fundamental for stock liquidity and investor confidence.

Why It Matters

This filing confirms ATAI Life Sciences N.V.'s ongoing compliance with SEC regulations and its listing on the Nasdaq Global Market, which is crucial for the stock's trading and investor accessibility.

Risk Assessment

Risk Level: low — This 8-K filing is a standard procedural update and does not indicate any new financial or operational risks for the company.

Analyst Insight

A smart investor would note this routine filing as confirmation of ongoing regulatory compliance and market listing, which are foundational but not catalysts for immediate action. It reinforces the stability of the stock's trading environment.

Key Numbers

• €0.10 — par value per share (the stated value of each common share of ATAI Life Sciences N.V.)

Key Players & Entities

• ATAI Life Sciences N.V. (company) — the registrant filing the 8-K
• The Nasdaq Stock Market LLC (Nasdaq Global Market) (company) — the exchange where ATAI's shares are registered
• €0.10 (dollar_amount) — par value per share of common stock

Forward-Looking Statements

• ATAI Life Sciences N.V. will continue to maintain its listing on the Nasdaq Global Market. (ATAI Life Sciences N.V.) — high confidence, target: 2025-01-09

FAQ

Filing Documents

• ef20018358_8k.htm (8-K) — 29KB
• ef20018358_ex10-1.htm (EX-10.1) — 56KB
• 0001140361-24-001529.txt ( ) — 231KB
• atai-20240107.xsd (EX-101.SCH) — 4KB
• atai-20240107_lab.xml (EX-101.LAB) — 23KB
• atai-20240107_pre.xml (EX-101.PRE) — 16KB
• ef20018358_8k_htm.xml (XML) — 4KB

01

Item 8.01 Other Events On January 7, 2024, atai Life Sciences N.V. (the "Company"), ATAI Life Sciences AG ( "ATAI AG") and Christian Angermayer agreed to enter into the Termination and New Consultancy Agreement (the "2024 Consultancy Agreement. Pursuant to the 2024 Consultancy Agreement, the parties agreed to terminate the Consultancy Agreement between ATAI AG and Mr. Angermayer dated January 16, 2021(the "Original Consultancy Agreement") and enter into a new consultancy agreement between the Company and Mr. Angermayer to extend the term of the Original Consultancy Agreement to January 5, 2028, increase the services to include various business objectives (including related to business and finance, communication and investor relations), and provide for the grant of an option to purchase 1,658,094 shares of the Company that vests over four years in part based on continued service and in part based on the Company's total shareholder return compared to the four-year total shareholder return of the companies comprising the XBI. This summary is qualified in its entirety by reference to the full text of the 2024 Consultancy Agreement, a copy of which is attached as Exhibit 10.1 and incorporated herein by reference.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Termination and New Consultancy Agreement, by and among the Company, ATAI AG and Christian Angermayer, dated January 7, 2024. 104 Cover Page Interactive Data File (embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ATAI LIFE SCIENCES N.V. Date: January 9, 2024 By: /s/ Florian Brand Name: Florian Brand Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR